Eagle Health Investments LP
An institutional investment manager in Greenwich, CT. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 10, 2026. SEC CIK 1842545.
- Reported value$603.3m
- Positions27
Holdings: 27 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Argenx SEARGX | SPONSORED ADR | 04016X101 | 70.9 | 11.8% | 76,417 | Added+81 | |
| Icon Pub Ltd Co | SHS | G4705A100 | 53.5 | 8.9% | 308,143 | Reduced−50,357 | |
| Guardant Health IncGH | COM | 40131M109 | 45.1 | 7.5% | 300,685 | Reduced−9,596 | |
| Insmed IncINSM | COM PAR $.01 | 457669307 | 41.0 | 6.8% | 384,130 | Added+159,859 | |
| Biomarin Pharmaceutical IncBMRN | COM | 09061G101 | 35.7 | 5.9% | 624,676 | Added+118,867 | |
| Illumina IncILMN | COM | 452327109 | 33.0 | 5.5% | 187,413 | Unchanged | |
| Scholar Rock HLDG CorpSRRK | COM | 80706P103 | 30.5 | 5.1% | 555,272 | Added+61,253 | |
| Protagonist Therapeutics IncPTGX | COM | 74366E102 | 30.4 | 5.0% | 248,322 | Added+69,000 | |
| Ultragenyx Pharmaceutical inRARE | COM | 90400D108 | 29.5 | 4.9% | 884,121 | Unchanged | |
| Compass Pathways plcCMPS | SPONSORED ADS | 20451W101 | 29.2 | 4.8% | 2,060,427 | Unchanged | |
| Ascendis Pharma A/S | ORD SHS | K08588103 | 28.3 | 4.7% | 106,158 | New+106,158 | |
| Revolution Medicines IncRVMD | COM | 76155X100 | 22.5 | 3.7% | 120,346 | Added+882 | |
| Fortrea Holdings IncFTRE | COMMON STOCK | 34965K107 | 20.6 | 3.4% | 1,181,274 | Reduced−126,286 | |
| Kymera Therapeutics IncKYMR | COM | 501575104 | 19.1 | 3.2% | 166,148 | Added+20,332 | |
| Axsome Therapeutics Inc.AXSM | COM | 05464T104 | 15.9 | 2.6% | 65,051 | New+65,051 | |
| Boston Scientific CorpBSX | COM | 101137107 | 15.8 | 2.6% | 369,164 | Added+76,012 | |
| Alkermes plc | SHS | G01767105 | 15.6 | 2.6% | 297,302 | Added+58,629 | |
| Ionis Pharmaceuticals IncIONS | COM | 462222100 | 15.4 | 2.6% | 194,577 | New+194,577 | |
| Tempus Ai IncTEM | CL A | 88023B103 | 14.8 | 2.5% | 256,269 | Unchanged | |
| Dianthus Therapeutics IncDNTH | COM | 252828108 | 12.8 | 2.1% | 131,344 | New+131,344 | |
| Ataibeckley Inc | COM SHS | 04650F101 | 9.0 | 1.5% | 1,709,359 | Unchanged | |
| Avalo Therapeutics IncAVTX | COM NEW | 05338F306 | 4.3 | 0.7% | 235,093 | New+235,093 | |
| Natera IncNTRA | COM | 632307104 | 4.3 | 0.7% | 15,847 | Reduced−106,030 | |
| ELI Lilly & CoLLY | COM | 532457108 | 2.4 | 0.4% | 1,994 | New+1,994 | |
| Intuitive Surgical IncISRG | COM NEW | 46120E602 | 1.7 | 0.3% | 4,390 | Unchanged | |
| Immunocore Holdings plcIMCR | ADS | 45258D105 | 1.5 | 0.2% | 46,300 | Unchanged | |
| Perceptive Cap Solutions Cor | CL A ORD SHS | G70077105 | 0.4 | <0.1% | 37,686 | Unchanged |
Sold out: 7 positions
Held at the end of the quarter before and not reported this quarter.
| Issuer | Class | CUSIP | Reported value$ | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Ascendis Pharma A/S | SPONSORED ADR | 04351P101 | 0.0 | 0.0% | 0 | Sold out−86,650 | |
| Bridgebio Pharma IncBBIO | COM | 10806X102 | 0.0 | 0.0% | 0 | Sold out−267,031 | |
| Centessa Pharmaceuticals plc | SPONSORED ADS | 152309100 | 0.0 | 0.0% | 0 | Sold out−214,291 | |
| Procept Biorobotics CorpPRCT | COM | 74276L105 | 0.0 | 0.0% | 0 | Call | Sold out−90,000 |
| Procept Biorobotics CorpPRCT | COM | 74276L105 | 0.0 | 0.0% | 0 | Sold out−483,815 | |
| SPDR Series Trust | STATE STREET SPD | 78464A870 | 0.0 | 0.0% | 0 | Put | Sold out−730,000 |
| Terns Pharmaceuticals Inc | COM | 880881107 | 0.0 | 0.0% | 0 | Sold out−412,497 |
Source: SEC EDGAR, Form 13F-HR, accession 0001172661-26-003205 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.